Talk:Apalutamide

Could use a section on clinical trials
A section on clinical trials could note significant phase II results, and any progress on the phase III trials. - Rod57 (talk) 18:19, 8 February 2017 (UTC)
 * interim analysis of phase III SPARTAN announced "The median metastasis-free survival time was 40.5 months and 16.2 months in the apalutamide and placebo groups, respectively (hazard ratio, 0.28; 95% CI, 0.23–0.55; P < .001)." - awaiting publication ? - Rod57 (talk) 14:19, 12 February 2018 (UTC)

Formula
There is probably an error in the formula, as the benzene ring with cyano group should actually be a pyridine ring (as per IUPAC name). — Preceding unsigned comment added by Prohnily (talk • contribs) 07:40, 23 November 2017 (UTC)

Availability
The availability section is incorrect/outdated. The drug is also available in Europe: https://www.ema.europa.eu/en/medicines/human/EPAR/erleada 2A02:8106:258:3A00:6D5E:5C26:9A38:3B6 (talk) 10:11, 26 June 2020 (UTC)